Consolidated Planning Corp Invests $947,000 in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Consolidated Planning Corp acquired a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 11,286 shares of the medical instruments supplier's stock, valued at approximately $947,000. Consolidated Planning Corp owned approximately 0.05% of LeMaitre Vascular as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the company. Opal Wealth Advisors LLC acquired a new position in shares of LeMaitre Vascular in the 1st quarter valued at about $26,000. NBC Securities Inc. purchased a new position in LeMaitre Vascular during the first quarter valued at approximately $36,000. Smartleaf Asset Management LLC grew its position in LeMaitre Vascular by 234.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock valued at $39,000 after purchasing an additional 293 shares in the last quarter. CBIZ Investment Advisory Services LLC increased its stake in LeMaitre Vascular by 38.5% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock valued at $39,000 after buying an additional 117 shares during the period. Finally, Huntington National Bank lifted its position in LeMaitre Vascular by 64.9% in the 4th quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock worth $107,000 after buying an additional 455 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Oppenheimer cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Barrington Research cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Finally, Lake Street Capital boosted their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, LeMaitre Vascular has an average rating of "Hold" and a consensus target price of $97.83.

Insider Activity at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 18,733 shares of the business's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $84.77, for a total value of $1,587,996.41. Following the completion of the sale, the chief executive officer now directly owns 1,873,651 shares in the company, valued at approximately $158,829,395.27. The trade was a 0.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders have sold 100,000 shares of company stock valued at $8,556,857. Corporate insiders own 9.50% of the company's stock.

LeMaitre Vascular Stock Down 2.5%

Shares of LMAT traded down $2.14 during mid-day trading on Thursday, hitting $82.40. 165,873 shares of the company's stock were exchanged, compared to its average volume of 170,541. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of 41.62, a P/E/G ratio of 2.23 and a beta of 0.83. The firm has a fifty day moving average of $83.82 and a two-hundred day moving average of $89.08. The company has a quick ratio of 13.83, a current ratio of 16.49 and a debt-to-equity ratio of 0.48. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.53% and a net margin of 19.96%. The business had revenue of $59.87 million during the quarter, compared to the consensus estimate of $57.61 million. During the same quarter in the prior year, the company posted $0.44 earnings per share. The company's revenue for the quarter was up 12.0% on a year-over-year basis. On average, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th were issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date of this dividend was Thursday, May 15th. LeMaitre Vascular's dividend payout ratio is 40.40%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.